Chris’s note: By now, you’ve probably heard the amazing news: In a world first, RiskHedge stock Intellia (NTLA) has successfully edited genes inside the human body in a clinical trial. This is a huge deal… a monumental scientific breakthrough in the field of genomics.
If you’ve been following RiskHedge, you know we’ve recommended genomic stocks for over a year now. The whole sector got a big boost after Intellia’s great news. And while we still like genomics stocks here, there’s a brand-new, earlier-stage sector we’re focused on, too...
In fact, as Chief Trader Justin Spittler shows below, this sector has all the makings of becoming GENOMICS 2.0.
With the markets closed today, we’re sharing Justin’s original essay on this exciting new sector, first published back in March. You’ll see why these specific stocks make genomics look like a sideshow… and how 3,000%─6,000% gains are possible for those who get in early…
Introducing “Genomics 2.0”…
Less than 1 in 1,000 investors are aware of what’s unfolding…
But what I’m about to show you might be the single-best early-stage investing opportunity of the 2020s.
Investors who act now could see gains of 3,000% to 6,000%...
And if history repeats itself, those gains will come rather quickly – within a year or two.
Because a brand-new industry is quietly taking shape...
And for once, ordinary investors have the rare chance to get in on the “ground floor.”
But there’s one catch:
You can’t play this the “lazy” way.
Because this trend is so new, there are no ETFs, no mutual funds, no “baskets of stocks” to play it.
We’re that early.
The only way to play this is to buy the correct individual stocks.
These stocks are small and under the radar. But as I’ll show you, anyone with a brokerage account can buy them...
In short: Today’s opportunity is a direct way to play what I call “Genomics 2.0”…
If you aren’t familiar, genomics is the study of all of a person’s genes… or their “genome.”
While genetics is concerned with individual genes and the traits they pass on to the next generation, genomics is more comprehensive.
By understanding all of our genes and how they interact with each other, scientists can discover secrets embedded in our DNA.
Through genomics, scientists have made major medical breakthroughs...
One has been a huge leap in progress in “precision medicine.” Which, in short, allows doctors to customize treatments for individual patients to make them more effective.
Scientists can also “edit” genes using CRISPR technology… which allows them to cut out bad genes that cause disease, and replace them with healthy genes.
And just 9 days ago… in arguably the biggest scientistic breakthrough of the 21st century, we’ve learned we can now edit genes inside the human body.
RiskHedge stock Intellia (NTLA) successfully demonstrated it could be done… And it’s a massive victory not just for the industry, but humanity.
If you’ve been following my work, you know I’ve been pounding the table on genomics stocks for over a year now...
In April 2020, I recommended CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Invitae Corporation (NVTA). Those 3 picks have seen peak gains of 311%, 312%, and 268%.
Other genomics stocks have soared even higher…
Pacific Biosciences (PACB) went on a tear recently, soaring more than 2,000% between last April and this February.
Genomics pioneer Exact Sciences (EXAS) surged more than 3,100% from early 2016 to this March.
And Bionano Genomics (BNGO) skyrocketed 6,200% from March 2020 to March 2021. That’s enough to turn every $10,000 invested into over $630,000!
These are truly life-changing returns. A single investment in any of these stocks could allow you to retire a decade early.
And I have no doubt that certain genomics stocks will continue to deliver market-beating returns for years to come…
But as a sector, the cat’s out of the bag.
Genomics stocks are all over the news now after Intellia’s groundbreaking announcement.
In other words, it’s no longer a ground-floor opportunity. The easy money in genomics has already been made.
But in Genomics 2.0... I believe the “easy money” is still very much on the table.
By “easy money,” I mean the large, often fast gains that come from investing in a new sector before anyone else.
That’s because Genomics 2.0 is the newest industry on earth.
I’m talking about proteomics… or the study of your body’s proteins.
If this is the first time you’re hearing of proteomics, you’re not alone. I’ve never seen it written about in any investing publication, outside of RiskHedge. As I said, this is truly an early-stage, ground-floor opportunity.
When most people hear “protein” they probably think of “high-protein foods” like beef or eggs. But proteins are far more important than a big juicy steak…
They are the building blocks of every living thing on earth. Inside your body, billions of tiny biological nanomachines called proteins are hard at work.
Proteins allow your eyes to detect light, your brain to think, and your blood to carry oxygen. Proteins allow your body to battle infections, and convert what you eat into nutrients.
And here’s what most people don’t realize: Your proteins are even more important than your genes. Don’t just take my word for it…
The New York Times recently said:
“Genes tend to get more attention, but proteins might really deserve the limelight.”
In other words…
Genomics is the sideshow: Proteomics is the main event.
And investing in proteomics today could be like turning back the clock and buying genomics stocks 2 years ago… before they handed out the massive gains I showed you earlier.
According to renowned medical research facility the Baker Institute, proteomics provides 1,000X more information than DNA.
My colleague Stephen McBride and I recently chatted with a PhD geneticist who told us: “Genomics is fun, but the real breakthroughs will come from proteomics.”
In short, proteomics is the next frontier of technology.
Scientists believe it could one day cure human aging...
Allow us to design bacteria that scrub pollution from earth’s atmosphere...
And even eradicate some of today’s worst diseases, like Alzheimer’s.
The potential of proteomics is mind-blowing…
Until recently, the sheer number of proteins in our bodies, along with their complexity, have kept proteomics confined to college science labs.
But that officially changed in November…
That’s when Google’s powerful AI supercomputer called DeepMind finally solved the “protein folding problem” that had been baffling scientists for 60 years.
Scientific journals called it a “conundrum of science.”
But it’s finally been solved… and it’s opened up a whole new world of investing opportunity.
But remember: This opportunity is so new, there isn’t even an ETF to play it yet.
The ONLY way to take advantage is with the right individual stocks… and there are only a handful of them out there.
Chief Analyst Stephen McBride and I recently uncovered one such proteomics stock. It’s a BUY right now.
This company is a pioneer in the proteomics industry.
It’s spent the last seven years and close to $200 million developing its “proteomics on a chip” devices, which will allow scientists to sequence proteins faster and cheaper than ever before.
This stock is displaying major strength. We’re seeing relentless buying, likely from institutions and hedge funds. When these big-money movers zero in on a small stock like this one, it can propel the price higher for years.
You can access this trade, name… ticker… and our specific game plan, as well as 4 other explosive “buy now” trades in our new report.
Learn how you can access this report here.
Chief Trader, RiskHedge